BACKGROUND: Several recent studies have provided evidence that polymorphisms in the telomerase reverse transcriptase (TERT) gene sequence are associated with cancer development, but a comprehensive synopsis is not available. We conducted a systematic review and meta-analysis of the available molecular epidemiology data regarding the association between TERT locus polymorphisms and predisposition to cancer. METHODS: A systematic review of the English literature was conducted by searching PubMed, Embase, Cancerlit, Google Scholar, and ISI Web of Knowledge databases for studies on associations between TERT locus polymorphisms and cancer risk. Random-effects meta-analysis was performed to pool per-allele odds ratios for TERT locus polymorphisms and risk of cancer, and between-study heterogeneity and potential bias sources (eg, publication and chasing bias) were assessed. Because the TERT locus includes the cleft lip and palate transmembrane 1-like (CLPTM1L) gene, which is in linkage disequilibrium with TERT, CLPTM1L polymorphisms were also analyzed. Cumulative evidence for polymorphisms with statistically significant associations was graded as "strong," "moderate," and "weak" according to the Venice criteria. The joint population attributable risk was calculated for polymorphisms with strong evidence of association. RESULTS: Eighty-five studies enrolling 490 901 subjects and reporting on 494 allelic contrasts were retrieved. Data were available on 67 TERT locus polymorphisms and 24 tumor types, for a total of 221 unique combinations of polymorphisms and cancer types. Upon meta-analysis, a statistically significant association with the risk of any cancer type was found for 22 polymorphisms. Strong, moderate, and weak cumulative evidence for association with at least one tumor type was demonstrated for 11, 9, and 14 polymorphisms, respectively. For lung cancer, which was the most studied tumor type, the estimated joint population attributable risk for three polymorphisms (TERT rs2736100, intergenic rs4635969, and CLPTM1L rs402710) was 41%. Strong evidence for lack of association was identified for five polymorphisms in three tumor types. CONCLUSIONS: To our knowledge, this is the largest collection of data for associations between TERT locus polymorphisms and cancer risk. Our findings support the hypothesis that genetic variability in this genomic region can modulate cancer susceptibility in humans.
BACKGROUND: Several recent studies have provided evidence that polymorphisms in the telomerase reverse transcriptase (TERT) gene sequence are associated with cancer development, but a comprehensive synopsis is not available. We conducted a systematic review and meta-analysis of the available molecular epidemiology data regarding the association between TERT locus polymorphisms and predisposition to cancer. METHODS: A systematic review of the English literature was conducted by searching PubMed, Embase, Cancerlit, Google Scholar, and ISI Web of Knowledge databases for studies on associations between TERT locus polymorphisms and cancer risk. Random-effects meta-analysis was performed to pool per-allele odds ratios for TERT locus polymorphisms and risk of cancer, and between-study heterogeneity and potential bias sources (eg, publication and chasing bias) were assessed. Because the TERT locus includes the cleft lip and palate transmembrane 1-like (CLPTM1L) gene, which is in linkage disequilibrium with TERT, CLPTM1L polymorphisms were also analyzed. Cumulative evidence for polymorphisms with statistically significant associations was graded as "strong," "moderate," and "weak" according to the Venice criteria. The joint population attributable risk was calculated for polymorphisms with strong evidence of association. RESULTS: Eighty-five studies enrolling 490 901 subjects and reporting on 494 allelic contrasts were retrieved. Data were available on 67 TERT locus polymorphisms and 24 tumor types, for a total of 221 unique combinations of polymorphisms and cancer types. Upon meta-analysis, a statistically significant association with the risk of any cancer type was found for 22 polymorphisms. Strong, moderate, and weak cumulative evidence for association with at least one tumor type was demonstrated for 11, 9, and 14 polymorphisms, respectively. For lung cancer, which was the most studied tumor type, the estimated joint population attributable risk for three polymorphisms (TERTrs2736100, intergenic rs4635969, and CLPTM1Lrs402710) was 41%. Strong evidence for lack of association was identified for five polymorphisms in three tumor types. CONCLUSIONS: To our knowledge, this is the largest collection of data for associations between TERT locus polymorphisms and cancer risk. Our findings support the hypothesis that genetic variability in this genomic region can modulate cancer susceptibility in humans.
Authors: Emily Webb; Peter Broderick; Steven Lubbe; Ian Chandler; Ian Tomlinson; Richard S Houlston Journal: Eur J Hum Genet Date: 2009-05-27 Impact factor: 4.246
Authors: Robert J Clifford; Jinghui Zhang; Daoud M Meerzaman; Myung-Soo Lyu; Ying Hu; Constance M Cultraro; Richard P Finney; Jenny M Kelley; Sol Efroni; Sharon I Greenblum; Cu V Nguyen; William L Rowe; Sweta Sharma; Gang Wu; Chunhua Yan; Hongen Zhang; Young-Hwa Chung; Jeong A Kim; Neung Hwa Park; Il Han Song; Kenneth H Buetow Journal: Hepatology Date: 2010-12 Impact factor: 17.425
Authors: Rayjean J Hung; Cornelia M Ulrich; Ellen L Goode; Yonathan Brhane; Kenneth Muir; Andrew T Chan; Loic Le Marchand; Joellen Schildkraut; John S Witte; Rosalind Eeles; Paolo Boffetta; Margaret R Spitz; Julia G Poirier; David N Rider; Brooke L Fridley; Zhihua Chen; Christopher Haiman; Fredrick Schumacher; Douglas F Easton; Maria Teresa Landi; Paul Brennan; Richard Houlston; David C Christiani; John K Field; Heike Bickeböller; Angela Risch; Zsofia Kote-Jarai; Fredrik Wiklund; Henrik Grönberg; Stephen Chanock; Sonja I Berndt; Peter Kraft; Sara Lindström; Ali Amin Al Olama; Honglin Song; Catherine Phelan; Nicholas Wentzensen; Ulrike Peters; Martha L Slattery; Thomas A Sellers; Graham Casey; Stephen B Gruber; David J Hunter; Christopher I Amos; Brian Henderson Journal: J Natl Cancer Inst Date: 2015-08-29 Impact factor: 13.506
Authors: Quinn T Ostrom; Luc Bauchet; Faith G Davis; Isabelle Deltour; James L Fisher; Chelsea Eastman Langer; Melike Pekmezci; Judith A Schwartzbaum; Michelle C Turner; Kyle M Walsh; Margaret R Wrensch; Jill S Barnholtz-Sloan Journal: Neuro Oncol Date: 2014-07 Impact factor: 12.300
Authors: Carissa C Jones; Yuki Bradford; Christopher I Amos; William J Blot; Stephen J Chanock; Curtis C Harris; Ann G Schwartz; Margaret R Spitz; John K Wiencke; Margaret R Wrensch; Xifeng Wu; Melinda C Aldrich Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-03-20 Impact factor: 4.254
Authors: Ying Bao; Jennifer Prescott; Chen Yuan; Mingfeng Zhang; Peter Kraft; Ana Babic; Vicente Morales-Oyarvide; Zhi Rong Qian; Julie E Buring; Barbara B Cochrane; J Michael Gaziano; Edward L Giovannucci; JoAnn E Manson; Kimmie Ng; Shuji Ogino; Thomas E Rohan; Howard D Sesso; Meir J Stampfer; Charles S Fuchs; Immaculata De Vivo; Laufey T Amundadottir; Brian M Wolpin Journal: Gut Date: 2016-10-21 Impact factor: 23.059
Authors: Alexandra S Shadrina; Uljana A Boyarskikh; Natalja A Oskina; Tatiana V Sinkina; Alexandr F Lazarev; Valentina D Petrova; Maxim L Filipenko Journal: Tumour Biol Date: 2014-10-10
Authors: David A Hinds; Kimberly E Barnholt; Ruben A Mesa; Amy K Kiefer; Chuong B Do; Nicholas Eriksson; Joanna L Mountain; Uta Francke; Joyce Y Tung; Huong Marie Nguyen; Haiyu Zhang; Linda Gojenola; James L Zehnder; Jason Gotlib Journal: Blood Date: 2016-06-30 Impact factor: 22.113